Novo Nordisk's (NYSE: NVO) Ozempic is so popular that it's practically self-marketing. For shareholders, that popularity has translated into achieving a total return of 48% over the past 12 months. And so it's natural for investors to wonder where to look for the next big thing so as to position themselves for the largest gains down the line.

While there's no predicting the future, right now there's enough evidence to make a case for the hottest biopharma field of tomorrow: longevity. Here's why.

Getting older is a fact of life, but experiencing diminished health as a result isn't necessarily inevitable. There's no fountain of youth awaiting discovery, but it's reasonable to expect that in the coming years there will be medicines or interventions developed to help people live longer and healthier lives by addressing the biological impacts of aging.

Continue reading

Source Fool.com